» Articles » PMID: 16239431

Impact of Posttransplantation G-CSF on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation

Abstract

Granulocyte colony-stimulating factor (G-CSF) is often administered after hematopoietic-cell transplantation (HCT) to accelerate neutrophil recovery, but it is unclear what impact G-CSF has on long-term transplantation outcomes. We analyzed within the database of the Center for International Blood and Marrow Transplant Research the impact of giving posttransplantation G-CSF on the outcomes of allogeneic HCT for acute myelogenous leukemia and chronic myelogenous leukemia in 2719 patients who underwent transplantation between 1995 and 2000. These included 1435 recipients of HLA-identical sibling bone marrow (BM), 609 recipients of HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelated donor BM transplants. Outcomes were compared between patients receiving or not receiving G-CSF within 7 days of HCT according to graft type. Median follow-up was more than 30 months (range, 2-87 months). G-CSF shortened the posttransplantation neutropenic period, but did not affect days +30 and +100 treatment-related mortality (TRM). Probabilities of acute and chronic graft-versus-host disease (GVHD), leukemia-free survival (LFS), and overall survival were similar whether or not G-CSF was given. Multivariate analyses confirmed that giving G-CSF did not affect the risk of GVHD, TRM, LFS, or survival. In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery.

Citing Articles

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?.

Alnughmush A, Sayyed A, Remberger M, Al-Shaibani E, Chen C, Chiarello C Transplant Direct. 2025; 11(2):e1753.

PMID: 39802196 PMC: 11723673. DOI: 10.1097/TXD.0000000000001753.


Stem cell graft dose and composition could impact on the expansion of donor-derived clones after allogeneic hematopoietic stem cell transplantation - a virtual clinical trial.

Stiehl T Front Immunol. 2024; 15:1321336.

PMID: 39737169 PMC: 11682905. DOI: 10.3389/fimmu.2024.1321336.


Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.

Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H Am J Hematol. 2024; 100(1):66-77.

PMID: 39564683 PMC: 11625993. DOI: 10.1002/ajh.27521.


Post-transplant G-CSF impedes engraftment of gene-edited human hematopoietic stem cells by exacerbating p53-mediated DNA damage response.

Araki D, Chen V, Redekar N, Salisbury-Ruf C, Luo Y, Liu P Cell Stem Cell. 2024; 32(1):53-70.e8.

PMID: 39536761 PMC: 11698648. DOI: 10.1016/j.stem.2024.10.013.


The Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on Early Complications and Graft-Versus-Host Disease (GVHD) in Allogeneic Stem Cell Transplantation (ASCT) Recipients.

Aydin Kaynar L, Ozkurt Z Cureus. 2023; 15(9):e46105.

PMID: 37779681 PMC: 10534265. DOI: 10.7759/cureus.46105.


References
1.
Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P . G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003; 32(2):217-23. DOI: 10.1038/sj.bmt.1704108. View

2.
Ho V, Mirza N, Junco Dd D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003; 32(8):771-5. DOI: 10.1038/sj.bmt.1704228. View

3.
Ringden O, Labopin M, Gorin N, Le Blanc K, Rocha V, Gluckman E . Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for.... J Clin Oncol. 2003; 22(3):416-23. DOI: 10.1200/JCO.2004.06.102. View

4.
Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A . Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol. 1989; 17(10):1047-50. View

5.
Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T . Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet. 1990; 336(8728):1417-20. DOI: 10.1016/0140-6736(90)93111-2. View